-- Shukra Pharmaceuticals（孟買證券交易所代碼：524632）公佈，截至3月31日的第四財季，公司綜合淨虧損1720萬印度盧比，而去年同期盈利5390萬盧比。 該公司股價在近期交易中下跌5%。 根據週四提交給印度證券交易所的文件，該公司每股虧損0.04盧比，去年同期每股獲利0.12盧比。 第四財季淨銷售額從去年同期的1.327億盧比下滑至6,320萬盧比。
Related Articles
Asia
Jefferies Adjusts Tokyo Electron's Price Target to 59,000 Yen From 48,000 Yen, Keeps at Buy
Tokyo Electron (TYO:8035) has an average rating of overweight and mean price target of 51,813.64 yen, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$TYO:8035
Asia
Singapore-listed Aspial Corp Buys Back More Shares
Aspial Corp. (SGX:A30) bought back 400,000 shares in the open market on Friday for SG$59,454.According to a same-day filing with the Singapore Exchange, the jewelry and real estate company has bought back 1,150,000 shares since its mandate of daily share repurchases started April 28.
$SGX:A30
Asia
Jefferies Adjusts Blue Star's Price Target to INR1,735 From INR1,665, Keeps at Hold
Blue Star (NSE:BLUESTARCO, BOM:500067) has an average rating of hold and mean price target of 1,836.04 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$BOM:500067$NSE:BLUESTARCO